84 related articles for article (PubMed ID: 9789786)
1. Differential release of endotoxin from Pseudomonas aeruginosa treated with beta-lactam antibiotics and its effect on the lethal activity.
Narita K; Koide N; Morikawa A; Kato Y; Sugiyama T; Yoshida T; Yokochi T
Jpn J Med Sci Biol; 1997 Dec; 50(6):233-9. PubMed ID: 9789786
[TBL] [Abstract][Full Text] [Related]
2. Quantitative variations in beta-lactam antibiotic released endotoxin from Pseudomonas aeruginosa: in-vivo relevance.
Jackson JJ; Kropp H
Prog Clin Biol Res; 1995; 392():235-51. PubMed ID: 8524928
[No Abstract] [Full Text] [Related]
3. [An experimental study of the LPS release from gram-negative bacteria induced by antibiotics (Part two)].
Xu N; Yuan J; Xiao G; Zheng J; Qin X
Zhonghua Shao Shang Za Zhi; 2002 Apr; 18(2):92-4. PubMed ID: 12515654
[TBL] [Abstract][Full Text] [Related]
4. [Inhibitory effect of egg white lysozyme on ceftazidime-induced release of endotoxin from Pseudomonas aeruginosa].
Liang AH; Xue BY; Liang RX; Wang JH; Wang D
Yao Xue Xue Bao; 2003 Nov; 38(11):801-4. PubMed ID: 14991988
[TBL] [Abstract][Full Text] [Related]
5. Biological characterization of endotoxins released from antibiotic-treated Pseudomonas aeruginosa and Escherichia coli.
Kirikae T; Kirikae F; Saito S; Tominaga K; Tamura H; Uemura Y; Yokochi T; Nakano M
Antimicrob Agents Chemother; 1998 May; 42(5):1015-21. PubMed ID: 9593119
[TBL] [Abstract][Full Text] [Related]
6. Continuous administration of PBP-2- and PBP-3-specific beta-lactams causes higher cytokine responses in murine Pseudomonas aeruginosa and Escherichia coli sepsis.
Buijs J; Dofferhoff AS; Mouton JW; van der Meer JW
J Antimicrob Chemother; 2007 May; 59(5):926-33. PubMed ID: 17395686
[TBL] [Abstract][Full Text] [Related]
7. [Effects of isepamicin and beta-lactam antibiotics on the release of endotoxin from Pseudomonas aeruginosa].
Yamaguchi S; Sato S; Toriya M; Tsuji A
Jpn J Antibiot; 1999 Jan; 52(1):41-56. PubMed ID: 10202687
[TBL] [Abstract][Full Text] [Related]
8. Evidence for antibiotic-mediated endotoxin release as a contributing factor to lethality in experimental gram-negative sepsis.
Morrison DC; Bucklin SE
Scand J Infect Dis Suppl; 1996; 101():3-8. PubMed ID: 9060044
[TBL] [Abstract][Full Text] [Related]
9. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response.
Ciofu O
APMIS Suppl; 2003; (116):1-47. PubMed ID: 14692154
[TBL] [Abstract][Full Text] [Related]
10. Simple method to determine beta-lactam resistance phenotypes in Pseudomonas aeruginosa using the disc agar diffusion test.
Vedel G
J Antimicrob Chemother; 2005 Oct; 56(4):657-64. PubMed ID: 16144872
[TBL] [Abstract][Full Text] [Related]
11. Comparison of beta-lactams in counter-selecting resistance of Pseudomonas aeruginosa.
Tam VH; Schilling AN; Melnick DA; Coyle EA
Diagn Microbiol Infect Dis; 2005 Jun; 52(2):145-51. PubMed ID: 15964503
[TBL] [Abstract][Full Text] [Related]
12. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
Burgess DS; Frei CR
J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664
[TBL] [Abstract][Full Text] [Related]
13. Effect of beta-lactam antibiotics on the in vitro development of resistance in Pseudomonas aeruginosa.
Carsenti-Etesse H; Cavallo JD; Roger PM; Ziha-Zarifi I; Plesiat P; Garrabe E; Dellamonica P
Chirurgia (Bucur); 2002; 97(2):151-9. PubMed ID: 12731225
[TBL] [Abstract][Full Text] [Related]
14. Use of Monte Carlo simulation to assess the pharmacodynamics of beta-lactams against Pseudomonas aeruginosa infections in children: a report from the OPTAMA program.
Ellis JM; Kuti JL; Nicolau DP
Clin Ther; 2005 Nov; 27(11):1820-30. PubMed ID: 16368453
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo potency of polymyxin B against IMP-type metallo-beta-lactamase-producing Pseudomonas aeruginosa.
Miyajima Y; Hiramatsu K; Mizukami E; Morinaga R; Ishii H; Shirai R; Kishi K; Tokimatsu I; Saikawa T; Kadota J
Int J Antimicrob Agents; 2008 Nov; 32(5):437-40. PubMed ID: 18715759
[TBL] [Abstract][Full Text] [Related]
16. Concentration-dependency of beta-lactam-induced filament formation in Gram-negative bacteria.
Buijs J; Dofferhoff AS; Mouton JW; Wagenvoort JH; van der Meer JW
Clin Microbiol Infect; 2008 Apr; 14(4):344-9. PubMed ID: 18261128
[TBL] [Abstract][Full Text] [Related]
17. Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps.
Ong CT; Tessier PR; Li C; Nightingale CH; Nicolau DP
Diagn Microbiol Infect Dis; 2007 Feb; 57(2):153-61. PubMed ID: 16930925
[TBL] [Abstract][Full Text] [Related]
18. Pseudomonas aeruginosa infections in the Intensive Care Unit: can the adequacy of empirical beta-lactam antibiotic therapy be improved?
Bhat S; Fujitani S; Potoski BA; Capitano B; Linden PK; Shutt K; Paterson DL
Int J Antimicrob Agents; 2007 Nov; 30(5):458-62. PubMed ID: 17703923
[TBL] [Abstract][Full Text] [Related]
19. Beta-lactam antibiotic-induced release of free lipopolysaccharide.
Hurley JC
J Infect Dis; 1993 Mar; 167(3):775-7. PubMed ID: 8440949
[No Abstract] [Full Text] [Related]
20. In vitro activity of newer broad spectrum beta-lactam antibiotics against enterobacteriaceae and non-fermenters: a report from Austrian intensive care units. Austrian Carbapenem Susceptibility Surveillance Group.
Krause R; Mittermayer H; Feierl G; Allerberger F; Wendelin I; Hirschl A; Reisinger EC
Wien Klin Wochenschr; 1999 Jul; 111(14):549-54. PubMed ID: 10467641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
